Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock

NCT04020263 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

610

Enrollment

OTHER

Sponsor class

Conditions

Cardiogenic Shock

Interventions

DRUG: Levosimendan 2.5 MG/ML Injectable Solution
DRUG: Placebo

Sponsor

Pr Bruno LEVY